表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）一线抗血管内皮生长因子（VEGF）联合表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）：将ARTEMIS试验纳入当前证据拼图。 - Suppr

Suppr

超能文献

First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence.

作者信息

Hafner Susanne

机构信息

Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University, D-89081, Ulm, Germany.

出版信息

Signal Transduct Target Ther. 2021 Dec 6;6(1):417. doi: 10.1038/s41392-021-00813-y.

DOI:10.1038/s41392-021-00813-y

PMID:34873145

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8648794/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45dc/8648794/6e3500dabe96/41392_2021_813_Fig1_HTML.jpg

相似文献

First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence.表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）一线抗血管内皮生长因子（VEGF）联合表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）：将ARTEMIS试验纳入当前证据拼图。

Signal Transduct Target Ther. 2021 Dec 6;6(1):417. doi: 10.1038/s41392-021-00813-y.

ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC.ARTEMIS 研究强调血管内皮生长因子抑制剂是 EGFR 突变型 NSCLC 中表皮生长因子受体酪氨酸激酶抑制剂的有效伙伴。

Cancer Cell. 2021 Sep 13;39(9):1178-1180. doi: 10.1016/j.ccell.2021.07.017. Epub 2021 Aug 12.

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.克唑替尼联合或不联合 EGFR-TKI 治疗 EGFR 突变型 NSCLC 患者 EGFR-TKI 治疗失败后获得性 MET 扩增：一项多中心回顾性研究。

J Transl Med. 2019 Feb 21;17(1):52. doi: 10.1186/s12967-019-1803-9.

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).ACTIVE 研究方案：阿帕替尼或安慰剂联合吉非替尼作为表皮生长因子受体突变型晚期非小细胞肺癌（CTONG1706）患者的一线治疗。

Cancer Commun (Lond). 2019 Nov 7;39(1):69. doi: 10.1186/s40880-019-0414-4.

Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC).转移性表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）的第三代EGFR酪氨酸激酶抑制剂格局

Expert Rev Anticancer Ther. 2019 Jun;19(6):431-435. doi: 10.1080/14737140.2019.1604228. Epub 2019 Apr 14.

Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.表皮生长因子受体（EGFR）突变阳性非小细胞肺癌患者一线 EGFR 酪氨酸激酶抑制剂治疗后治疗模式的观察性研究。

Adv Ther. 2020 Feb;37(2):946-954. doi: 10.1007/s12325-020-01221-4. Epub 2020 Jan 18.

Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.一线治疗晚期低丰度突变非小细胞肺癌（NSCLC）时，单独使用表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）或联合化疗的疗效。

Lung Cancer. 2019 Feb;128:6-12. doi: 10.1016/j.lungcan.2018.12.007. Epub 2018 Dec 6.

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.携带非常见 EGFR 突变的转移性非小细胞肺癌患者的治疗临床结局。

BMC Cancer. 2019 Jul 17;19(1):701. doi: 10.1186/s12885-019-5913-9.

Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer.EGFR 突变型晚期非小细胞肺癌个体化治疗进展。

Proc Jpn Acad Ser B Phys Biol Sci. 2020;96(7):266-272. doi: 10.2183/pjab.96.020.

Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.含内皮 PAS 结构域蛋白 1 通过介导非小细胞肺癌细胞中的表皮生长因子受体（EGFR）和间质-上皮转化因子（MET）通路赋予对酪氨酸激酶抑制剂（TKI）的抗性。

Cancer Biol Ther. 2015;16(4):549-57. doi: 10.1080/15384047.2015.1016689. Epub 2015 Apr 1.

引用本文的文献

Dauricine Overcomes Osimertinib Resistance in Lung Cancer by Inducing Ferroptosis via Stabilizing SAT1.蝙蝠葛碱通过稳定SAT1诱导铁死亡克服肺癌对奥希替尼的耐药性。

Cancer Sci. 2025 Aug;116(8):2256-2269. doi: 10.1111/cas.70113. Epub 2025 Jun 8.

Simultaneous Administration of Bevacizumab with Bee-Pollen Extract-Loaded Hybrid Protein Hydrogel NPs Is a Promising Targeted Strategy against Cancer Cells.同时给予贝伐单抗联合载蜂花粉提取物杂合蛋白水凝胶 NPs 是一种有前途的针对癌细胞的靶向策略。

Int J Mol Sci. 2023 Feb 10;24(4):3548. doi: 10.3390/ijms24043548.

[Advances of Immunotherapy Resistance and Coping Strategies  in Non-small Cell Lung Cancer].[非小细胞肺癌免疫治疗耐药性及应对策略的研究进展]

Zhongguo Fei Ai Za Zhi. 2023 Jan 20;26(1):66-77. doi: 10.3779/j.issn.1009-3419.2023.102.03.

Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance.非小细胞肺癌靶向治疗：药物及耐药机制。

Int J Mol Sci. 2022 Dec 1;23(23):15056. doi: 10.3390/ijms232315056.

本文引用的文献

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.贝伐珠单抗联合厄洛替尼治疗中国未经治疗的EGFR突变晚期非小细胞肺癌患者（ARTEMIS-CTONG1509）：一项多中心3期研究。

Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. doi: 10.1016/j.ccell.2021.07.005. Epub 2021 Aug 12.

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.厄洛替尼联合贝伐珠单抗对比厄洛替尼单药作为 EGFR 突变阳性非鳞状非小细胞肺癌一线治疗：随机 JO25567 研究的生存随访结果。

Lung Cancer. 2021 Jan;151:20-24. doi: 10.1016/j.lungcan.2020.11.020. Epub 2020 Nov 20.

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced -Mutated Non-small Cell Lung Cancer: A Meta-Analysis.表皮生长因子受体（EGFR）抑制剂联合抗血管生成药物作为晚期EGFR突变非小细胞肺癌患者一线治疗的疗效和安全性：一项荟萃分析

Front Oncol. 2020 Jun 25;10:904. doi: 10.3389/fonc.2020.00904. eCollection 2020.

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.雷莫芦单抗联合厄洛替尼治疗未经治疗的表皮生长因子受体突变型、晚期非小细胞肺癌患者（RELAY）：一项随机、双盲、安慰剂对照、III 期临床试验。

Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.

Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.厄洛替尼联合贝伐单抗与单用厄洛替尼对晚期表皮生长因子受体（EGFR）突变型非小细胞肺癌患者无进展生存期的影响：一项2期随机临床试验

JAMA Oncol. 2019 Oct 1;5(10):1448-1455. doi: 10.1001/jamaoncol.2019.1847.

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.厄洛替尼联合贝伐珠单抗对比厄洛替尼单药治疗表皮生长因子受体阳性的晚期非鳞状非小细胞肺癌（NEJ026）：一项开放标签、随机、多中心、III 期临床试验的期中分析。

Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.厄洛替尼联合贝伐珠单抗治疗表皮生长因子受体突变的晚期非小细胞肺癌患者（BELIEF）：一项国际、多中心、单臂、Ⅱ期临床试验。

Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10.

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.厄洛替尼单药或联合贝伐珠单抗作为 EGFR 突变的晚期非鳞状非小细胞肺癌患者的一线治疗（JO25567）：一项开放标签、随机、多中心、Ⅱ期研究。

Lancet Oncol. 2014 Oct;15(11):1236-44. doi: 10.1016/S1470-2045(14)70381-X. Epub 2014 Aug 27.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验